EUVIMEDEUVIMED entdecken
Crossref

The Potency Problem in GPCR Biased Agonism

Cassandra J. Hatzipantelis

ACS Chemical Neuroscience · 27.10.2026

DOI: 10.1021/acschemneuro.6c00783 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Neuroscience, online erschienen am 27.10.2026. Verfasst von Cassandra J. Hatzipantelis. Die Arbeit nennt 16 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biased agonism promised a new generation of GPCR therapeutics capable of selectively engaging beneficial signaling pathways while avoiding those associated with adverse effects. Yet contemporary bias metrics largely quantify signaling efficiency through potency-centric measures, emphasizing pathway preference over the pathway exclusion that may better align with the original promise of biased agonism. I argue that efficacy-centered descriptors, including a simple complementary E-factor (ΔΔlog(EMax)), may help identify ligands with therapeutically relevant functional selectivity and should be reported alongside conventional bias factors to provide a more complete assessment of biased signaling.

Zitieren

APA

Hatzipantelis, C. J. (2026). The Potency Problem in GPCR Biased Agonism. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.6c00783

Vancouver

Hatzipantelis CJ. The Potency Problem in GPCR Biased Agonism. ACS Chemical Neuroscience. 2026. doi:10.1021/acschemneuro.6c00783

BibTeX
@article{Hatzipantelis2026,
  author = {Hatzipantelis, Cassandra J.},
  title = {The Potency Problem in GPCR Biased Agonism},
  journal = {ACS Chemical Neuroscience},
  year = {2026},
  doi = {10.1021/acschemneuro.6c00783}
}
Kostenlos starten →